MwanzoBNTX • NASDAQ
add
BioNTech SE
Bei iliyotangulia
$ 97.28
Bei za siku
$ 95.57 - $ 97.69
Bei za mwaka
$ 81.20 - $ 129.27
Thamani ya kampuni katika soko
23.16B USD
Wastani wa hisa zilizouzwa
1.11M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.52B | 22.02% |
Matumizi ya uendeshaji wa biashara | 1.40B | 34.32% |
Mapato halisi | -28.70M | -114.49% |
Kiwango cha faida halisi | -1.89 | -111.88% |
Mapato kwa kila hisa | -0.12 | -114.81% |
EBITDA | 91.20M | 39.66% |
Asilimia ya kodi ya mapato | 216.19% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 14.53B | -13.06% |
Jumla ya mali | 21.34B | -4.73% |
Jumla ya dhima | 2.86B | -12.87% |
Jumla ya hisa | 18.48B | — |
hisa zilizosalia | 240.46M | — |
Uwiano wa bei na thamani | 1.27 | — |
Faida inayotokana na mali | -0.38% | — |
Faida inayotokana mtaji | -0.44% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -28.70M | -114.49% |
Pesa kutokana na shughuli | 780.70M | 222.19% |
Pesa kutokana na uwekezaji | -925.30M | -551.16% |
Pesa kutokana na ufadhili | -11.50M | -45.57% |
Mabadiliko halisi ya pesa taslimu | -176.60M | 76.52% |
Mtiririko huru wa pesa | 1.05B | 253.59% |
Kuhusu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
6,772
